Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets
Transfusion2015Vol. 55(6), pp. 1320–1326
Citations Over TimeTop 10% of 2015 papers
Gisela Scharbert, Léonore Wetzel, Waltraud C. Schrottmaier, Julia Barbara Kral, Thomas Weber, Alice Assinger
Abstract
Our results provide novel insights into potential differences between the P2Y12 inhibitors on donor PLT function in an in vitro setting, which may provide implications for future PLT transfusion strategies in these patients.
Related Papers
- → Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets(2015)24 cited
- → P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial(2016)14 cited
- → Ticagrelor or prasugrel in STEMI patients: a pharmacodynamic evaluation(2013)
- → ANTI-THROMBOCYTIC DRUGS FOR ACUTE CORONARY SYNDROME: DIRECT COMPARISON OF HEMORRHAGIC SAFETY THROMBOCYTE P2Y12-RECEPTOR BLOCKERS TICAGRELOR AND CLOPIDROGEL (BASED ON PLATO STUDY RESULTS(2016)
- → The effect of cessation of 2nd generation P2Y12 inhibitor therapy on platelet reactivity in patients 1 year after acute myocardial infarction(2018)